KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Goodwill (2020 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Goodwill for 3 consecutive years, with $117.0 million as the latest value for Q3 2024.

  • On a quarterly basis, Goodwill changed N/A to $117.0 million in Q3 2024 year-over-year; TTM through Sep 2024 was $117.0 million, a N/A change, with the full-year FY2023 number at $117.0 million, changed N/A from a year prior.
  • Goodwill was $117.0 million for Q3 2024 at Supernus Pharmaceuticals, roughly flat from $117.0 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $117.0 million in Q4 2023 to a low of $77.9 million in Q4 2020.
  • A 3-year average of $100.0 million and a median of $102.6 million in 2020 define the central range for Goodwill.